Zongertinib has been added to the NCCN guidelines. 7 days from approval (Aug 8) to addition (Aug 15) is great real-time speed underlining enthusiasm for approval.
NCCN encompasses "...oncogenic and likely oncogenic mutations" with a broader inclusion than TKD-restricted FDA